Business Wire

ReadSpeaker VoiceLab Powers Sonos Voice Control Custom Voice

17.5.2022 15:00:00 EEST | Business Wire | Press release

Share

ReadSpeaker, the most trusted, independent digital voice partner for global businesses, today announced that Sonos, the world’s leading sound experience company, has selected the ReadSpeaker VoiceLab to create a custom voice for Sonos Voice Control, the brand’s voice assistant. Sonos selected VoiceLab, ReadSpeaker’s custom voice production unit, because of the company’s proven experience and expertise in state-of-the-art, AI-driven text-to-speech.

Leading consumer brands are looking to develop their own voice assistants to provide consistently on-brand, personalized and engaged automated customer experiences. Those with a visionary strategy and commitment to consumer privacy, like Sonos, are understanding the broader importance of AI-driven digital voice in helping expand their business and meet consumer needs and expectations, even as they quickly evolve.

The ReadSpeaker VoiceLab managed the development process, including carrying out recordings with Giancarlo Esposito, processing the recorded data, training Deep Neural Networking (DNN) models on that data, and managing quality control, delivery, and all necessary quality assurance steps. Because of the technicality of the voice recordings required to build the custom voice, which requires speech to be delivered in an extremely consistent way that prioritizes precise articulation and style, ReadSpeaker’s VoiceLab experts worked closely with Esposito throughout every stage of the process.

A key challenge in the development of this custom voice was the need for it to comprehend and pronounce non-standard text content that is often found in the music industry. It was also critical that the assistant was able to read artists’ track or album information in numerous languages. The VoiceLab team worked closely with Sonos and Esposito to optimize the speech output for this massively broad domain.

Sonos Voice Control is an entirely new voice experience that delivers fast, accurate hands-free control of your music and your Sonos system with unmatched privacy. Designed with privacy at its core, Sonos Voice Control is the simplest way to control your music, offering complete command of your Sonos system using only your voice. Sonos Voice Control works on every voice-capable Sonos speaker, processing requests entirely on the device. No audio or transcript is sent to the cloud, stored, listened to or read by anyone. Available from June 1 in the US and later this year in France on all voice capable Sonos products, Sonos Voice Control is compatible with Sonos Radio, Apple Music, Amazon Music, Deezer, and Pandora at launch. More services and markets will follow.

“We selected ReadSpeaker to power the custom voice for Sonos Voice Control for a variety of reasons, not least of which was their ability to work closely with us from the development phase all the way through delivery,” said Joseph Dureau, Vice President, Voice Experience, at Sonos. “ReadSpeaker’s approach to custom voice is innovative and extremely thorough – which is exactly what we required for this project – and the company’s dedicated linguistic team has been a critical tool for us throughout this project.”

“As brands become increasingly aware that, much like a visual logo, a custom voice ensures consistently engaging, on-brand interactions across touchpoints, our VoiceLab is developing voices that speak to their brand persona and create unique experiences,” said Roy Lindemann, CMO and CCO EMEA, at ReadSpeaker. “With more consumers leveraging digital voice every day for everything from making purchases to choosing which playlist to listen to, having a custom branded voice is becoming table stakes for delivering a quality, personalized CX in real time. By partnering with Sonos, we are helping to bring yet another brand’s voice to life in an exciting, innovative way.”

Watch the SVC Custom Voice “behind the scenes” video here: https://www.youtube.com/watch?v=vwJ8Ub10arQ

For more information about the ReadSpeaker VoiceLab, visit www.readspeaker.ai/solutions/custom-text-to-speech-tts-voices/.

About ReadSpeaker:
ReadSpeaker is the most trusted independent digital voice partner for global brands, institutions, and organizations. With over 20 years’ experience, ReadSpeaker’s AI-powered text-to-speech solutions and expert assistance enhance the accessibility of digital content and enable more user-friendly and engaging interactions with technology. The company’s flexible cloud and on-premise solutions bring over 110 expressive, humanlike synthetic voices in more than 35 languages to any application or device. The company consistently maintains its uncompromising commitment to data privacy and has so far speech enabled over 10,000 voice applications worldwide.

ReadSpeaker’s digital voice design brand, readspeaker.ai, helps agencies, integrators, and developers to enhance CX and drive sales through consistently engaging, on-brand interactions across touchpoints. For more information, go to readspeaker.ai and follow the company on Twitter and LinkedIn.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

ReadSpeaker:
Victoria Newell
V2 Communications for ReadSpeaker
readspeaker@v2comms.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release

2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr

Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye